Location of Repository

A review of evidence on non-invasive prenatal diagnosis (NIPD) : tests for fetal RHD genotype

By Karoline Freeman, Leeza Osipenko, Diane Clay, Julia Hyde, Ala Szczepura and HASH(0x55bfd7991fc8)

Abstract

This report concentrates on three main areas.\ud First and foremost, we set the background context for RhD NIPD in prenatal care. While the methodology chapter describes how the literature review was carried out and how additional information was collected, the second chapter provides an overview of the key issues associated with pregnancy of RhD negative women. We present background information based on publications from 1997 to 2006 which describe the genetic condition and its prevalence (RhD negativity) in populations, as well as the frequency of cases of sensitisation and HDN (haemolytic disease of the newborn). We also discuss current service provision for RhD negative women in a number of European countries and look at how the NIPD test might be set within current service contexts

Topics: RJ
Publisher: University of Warwick
Year: 2007
OAI identifier: oai:wrap.warwick.ac.uk:129

Suggested articles

Preview

Citations

  1. (2004). A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma.
  2. (2003). A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative HTA V.7,
  3. (2004). A review of the clinical effectiveness of routine prenatal anti-D prophylaxis for rhesus-negative women who are pregnant.
  4. Academy: Symphogen and Biovitrum enter into a collaboration for scale-up and production of clinical material for a recombinant polyclonal anti-D antibody preparation: www.mva.org).
  5. (2006). Accuracy of non-invasive fetal RH genotyping from maternal blood in the presence of RH gene rearrangements and the maternal alloimmunization. Poster from the Temple University of Medicine,
  6. AGM presentation 2003. Available online at [www.csl.com.au].
  7. (2004). Alloanti-D immunisation by weak D type 1 RBCs. Vox Sang.
  8. (2005). An earlier look at baby’s genes.
  9. (2005). Analysis of cell-free fetal DNA from maternal plasma and serum using a conventional multiplex PCR: Factors influencing success.
  10. and Cambridge Antibody Technology sign patent licensing agreement. Available online at [www.symphogen.com].
  11. (2001). Antenatal care in Europe: varying ways of providing highcoverage services.
  12. (2005). Antenatal care in the European Union: A survey on guidelines in all 25 member states of the Community.
  13. (2005). Anti-D administration in pregnancy for preventing Rhesus sensitisation. The Cochrane Database of Systematic Reviews
  14. (2005). Application of fetal DNA detection in maternal plasma: a prenatal diagnosis unit experience.
  15. Arthur Robinson): Life Therapeutics negotiate rights for UK recombinant therapeutic. Available online at [www.aar.com.au]. A Review of Evidence on Non-invasive Prenatal Diagnosis (NIPD): Tests for Fetal RHD Genotype
  16. Available online at [http://www.consort-statement.org/stardstatement.htm].
  17. Bioinformatics and Biostatistics. Available online at [http://www.cgal.icnet.uk/bioinformatics/link.jsp?path=content/how%20to/microarray%20dat a%20analysis/design/replicates.html].
  18. (2000). CHO expression of a novel human recombinant IgG1 anti-RhD antibody isolated by phage display.
  19. (1998). Detection of fetal RHD-specific sequences in maternal plasma. The Lancet 352:1196.
  20. (2003). Detection of fetal Rhesus D gene in a whole blood of women booking for routine prenatal care.
  21. (2003). Detection of fetal Rhesus D gene in whole blood of women booking for routine prenatal care.
  22. (2004). Efficacy and safety of a new, chromatographically purified rhesus(D) immunoglobulin.
  23. (2005). Emerging Prenatal Genetic Tests: Developing a Health Technology Assessment (HTA) Framework for Informed Decision-making.
  24. Empirical evidence of design-related bias in studies of diagnostic tests.
  25. (1991). Epidemiology of Rh hemolytic disease of the newborn in the United States.
  26. (2006). Ethnicity Questions and Antenatal Screening for Sickle Cell/Thalassaemia [EQUANS]. A Randomised Controlled Trial of Two Questionnaires. Ethnicity and Health
  27. (2003). Evaluation of the clinical usefulness of isolation of fetal DNA from the maternal circulation.
  28. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn.
  29. (2004). Fetal K1 genotyping from maternal plasma.
  30. (2005). Fetal RHD genotyping by maternal serum analysis: a two year experience.
  31. (2004). Fetal RHD genotyping from maternal plasma.
  32. (2002). Fetal RHD genotyping in maternal serum during the first trimester of pregnancy.
  33. (2005). Fetal RHD typing with free DNA in maternal plasma.
  34. (1987). Feto-maternal haemorrhage associated with genetic amniocentesis: results of a randomised trial.
  35. (2005). Final Report to UK Department of Health: Further developments of non-invasive prenatal diagnosis using maternal plasma/TCC as a source of fetal DNA.
  36. (2001). Genotyping fetal DNA by noninvasive means: extraction from maternal plasma Vox Sang 80:
  37. (2004). Grand Rounds: Rh disease: It’s still a threat.
  38. (2000). High sensitivity of fetal DNA in plasma compared to serum and nucleated cells using unnested PCR in maternal blood.
  39. (2005). High variability of the RH locus in different ethnic backgrounds.
  40. (2005). Identification of fetal genotype in utero using DNA extracted from maternal plasma.
  41. (2005). Immune response and tolerance to the RhD blood group protein in HLA-transgenic mice.
  42. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR.
  43. (1993). Isolating fetal cells from maternal blood. Advances in prenatal diagnosis through molecular technology.
  44. (2005). Kit said I’d have a boy…but my tot’s a girl. The Sunday Mail. Available at: www.sundaymail.co.uk/news
  45. (2004). Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women.
  46. (1999). Male fetuses are particularly affected by maternal sensitisation to D antigen.
  47. (2002). Management of rhesus alloimmunization in pregnancy.
  48. (2005). Meeting in
  49. (2003). Minimizing red blood cell contamination while isolating mononuclear cells from whole blood: the next step for the treatment of severe hemolytic disease of the fetus/newborn.
  50. (1997). Molecular analysis of Rh transcripts and polypeptides from individuals expressing the D VI variant phenotype: an RHD gene deletion event does not generate all D VI ccEe phenotypes.
  51. (1999). Molecular configuration of Rh D epitopes as defined site-directed mutagenesis and expression of mutant Rh constructs in K562 erythroleukemia cells.
  52. (2001). Monoclonal anti-D for immunoprophylaxis. Vox Sanguinis
  53. (2005). Non-invasive fetal RHD and RHCE genotyping from maternal plasma in alloimmunized pregnancies.
  54. (2005). Non-invasive Fetal RHD and RHCE Genotyping using real-time PCR testing of maternal plasma in RhD negative pregnancies.
  55. (2005). Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma.
  56. (2003). Non-invasive fetal sex determination using a conventional nested PCR analysis of fetal DNA in maternal plasma.
  57. (2004). Non-invasive foetal RhD typing and RhD negative pregnant women - prelim.
  58. Non-invasive prenatal DNA testing services.
  59. (1999). Non-invasive RNAbased determination of fetal Rhesus D type: a prospective study based on 96 pregnancies.
  60. (1999). Noninvasive determination of fetal RhD status using fetal DNA in maternal serum and PCR.
  61. (2005). Noninvasive prenatal diagnosis of fetal rhesus D. Ready for Prime(r) time. Obstetrics and Gynecology.
  62. (2002). Paternal leukocyte alloimmunization as a treatment for hemolytic disease of the newborn in a rabbit model.
  63. (2002). Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 42:1079-1085.
  64. (2002). Prediction of fetal RhD and Rh CcEe phenotype from maternal plasma with real-time PCR.
  65. (1994). Prenatal determination of fetal rhesus D status by DNA amplification of peripheral blood of rhesus-negative mothers.
  66. (2001). Prevention of maternal RhD isoimmunization with anti-D gamma globulin.
  67. (1998). Prevention of Rh haemolytic disease of the fetus and newborn – general background.
  68. (1998). Quantitative analysis of fetal DNA in maternal plasma and serum: implications for non-invasive prenatal diagnosis.
  69. (2005). Reliable test for prenatal prediction of fetal RhD type using maternal plasma from RhD negative women.
  70. (2005). Report of the first international workshop on molecular blood group genotyping.
  71. (1983). Rh isoimmunisation related to amniocentesis.
  72. (2001). RHD positive haplotypes in D negative Europeans.
  73. rhesus isoimmunization by preimplantation genetic diagnosis.
  74. (2001). Risk free simultaneous prenatal identification of fetal Rhesus D status and sex by multiplex real-time PCR using cell free fetal DNA in maternal plasma.
  75. (1999). Routine prenatal care in Europe: the comparative experience of nine departments of gynaecology and obstetrics in eight different countries.
  76. (2004). Screening for foetal RHD-genotype by plasma PCR in all D-negative pregnant women is feasible. Vox Sang 87 (Suppl3): Abstract (Tu07.04).
  77. (1996). Services Task Force.
  78. (1995). Single-cell analysis of the RhD blood type for use in preimplantation diagnosis in the prevention of severe haemolytic disease of the newborn.
  79. (1997). Specificity and sensitivity of RHD genotyping methods by PCR-based DNA amplification.
  80. (2005). Technology appraisal 41: Routine anti-D prophylaxis for pregnant women who are RhD negative. Available online at [http://www.nice.org.uk/page.aspx?o=31679]. Accessed on
  81. Test reveals gender early in pregnancy. The Boston Globe. Available at: www.boston.com/yourlife/health/women/articles/2005/06/27/test_reveals_gender_early_in _pregnancy/
  82. (2004). The complexities of the Rh system.
  83. (2000). The fetal and neonatal outcomes of Rhesus D antibody affected pregnancies in Northern Ireland.
  84. (1999). The incidence of irregular antibodies in pregnancy: a prospective study in the region of the ‘s-Hertogenbosch. Ned Tijdschr geneeskd.
  85. (1999). The psychosocial impact on high-risk pregnant women of a noninvasive prenatal diagnostic test.
  86. (2004). The Rh blood group system in review: A new face for the next decade.
  87. (2005). The role of preimplantation genetic diagnosis in the management of severe rhesus alloimmunization: first unaffected pregnancy: Case report.
  88. (1998). The scientific basis of prenatal prophylaxis.
  89. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment.
  90. (1997). Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review.
  91. (2004). Use of maternal plasma for non-invasive determination of foetal RhD status.
  92. (2005). Utilisation en routine clinique du génotypage foetal RHD sur plasma maternel: bilan de deux ans d’activité.
  93. (2003). Variation in the reliability of RHD prenatal genotyping using the polymerase chain reaction and targeting multiple exons of the RHD gene.
  94. (2005). ZonMw. Final Report Health Care Efficiency Research Programme on http://www.zonmw.nl.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.